PMID- 29374854
OWN - NLM
STAT- MEDLINE
DCOM- 20181231
LR  - 20181231
IS  - 1720-8386 (Electronic)
IS  - 0391-4097 (Linking)
VI  - 41
IP  - 9
DP  - 2018 Sep
TI  - Liraglutide ameliorates palmitate-induced insulin resistance through inhibiting 
      the IRS-1 serine phosphorylation in mouse skeletal muscle cells.
PG  - 1097-1102
LID - 10.1007/s40618-018-0836-x [doi]
AB  - OBJECTIVE: A reduction in insulin-stimulated glucose uptake in skeletal muscles 
      is a characteristic of insulin resistance and type 2 diabetes mellitus (T2DM). 
      The glucagon-like peptide (GLP)-1 agonist liraglutide can reduce blood glucose 
      levels in individuals with T2DM. However, its effect on insulin-induced glucose 
      metabolism in the skeletal muscle of insulin resistance is unknown. We 
      investigated the effects and action mechanisms of liraglutide on insulin 
      resistance (IR) in the skeletal muscle cells treatment with palmitic acid (PA). 
      METHODS: The cell-surface GLUT4myc levels were determined by an antibody-coupled 
      colorimetric assay. The phosphorylation levels of Akt, PI3K(p85alpha), AS160, IRS1, 
      IKK, and JNK were determined by western blotting. The quantifications of mRNA 
      levels of TNFalpha, IL-1beta, and IL-6 were determined by real-time PCR. Analysis of 
      variance was used for data analysis. RESULTS: PA elevated not only 
      phosphorylation of JNK, IRS1 serines, and IKKalpha/beta, but also the expression of 
      IL-6, TNFalpha and IL-1beta in C2C12-GLUT4myc cells. PA can reduce phosphorylation of 
      IRS1 tyrosine. These effects of PA were reversed by liraglutide. In addition, 
      liraglutide can reverse PA-decreased insulin-stimulated cell-surface GLUT4 
      levels, Akt, PI3K(p85alpha), and AS160 phosphorylation. CONCLUSIONS: Liraglutide can 
      enhance insulin-induced GLUT4 translocation by inhibiting IRS1 serine 
      phosphorylation in PA-treated muscle cells.
FAU - Li, Z
AU  - Li Z
AD  - Key Laboratory of Hormones and Development (Ministry of Health), Tianjin Key 
      Laboratory of Metabolic Diseases, Tianjin Metabolic Diseases Hospital, Tianjin 
      Institute of Endocrinology, Tianjin Medical University, Tianjin, 300070, China.
FAU - Zhu, Y
AU  - Zhu Y
AD  - Key Laboratory of Hormones and Development (Ministry of Health), Tianjin Key 
      Laboratory of Metabolic Diseases, Tianjin Metabolic Diseases Hospital, Tianjin 
      Institute of Endocrinology, Tianjin Medical University, Tianjin, 300070, China.
FAU - Li, C
AU  - Li C
AD  - Key Laboratory of Hormones and Development (Ministry of Health), Tianjin Key 
      Laboratory of Metabolic Diseases, Tianjin Metabolic Diseases Hospital, Tianjin 
      Institute of Endocrinology, Tianjin Medical University, Tianjin, 300070, China.
FAU - Tang, Y
AU  - Tang Y
AD  - Key Laboratory of Hormones and Development (Ministry of Health), Tianjin Key 
      Laboratory of Metabolic Diseases, Tianjin Metabolic Diseases Hospital, Tianjin 
      Institute of Endocrinology, Tianjin Medical University, Tianjin, 300070, China.
FAU - Jiang, Z
AU  - Jiang Z
AD  - Key Laboratory of Hormones and Development (Ministry of Health), Tianjin Key 
      Laboratory of Metabolic Diseases, Tianjin Metabolic Diseases Hospital, Tianjin 
      Institute of Endocrinology, Tianjin Medical University, Tianjin, 300070, China.
FAU - Yang, M
AU  - Yang M
AD  - Key Laboratory of Hormones and Development (Ministry of Health), Tianjin Key 
      Laboratory of Metabolic Diseases, Tianjin Metabolic Diseases Hospital, Tianjin 
      Institute of Endocrinology, Tianjin Medical University, Tianjin, 300070, China.
FAU - Ni, C-L
AU  - Ni CL
AD  - Key Laboratory of Hormones and Development (Ministry of Health), Tianjin Key 
      Laboratory of Metabolic Diseases, Tianjin Metabolic Diseases Hospital, Tianjin 
      Institute of Endocrinology, Tianjin Medical University, Tianjin, 300070, China.
FAU - Li, D
AU  - Li D
AD  - Key Laboratory of Hormones and Development (Ministry of Health), Tianjin Key 
      Laboratory of Metabolic Diseases, Tianjin Metabolic Diseases Hospital, Tianjin 
      Institute of Endocrinology, Tianjin Medical University, Tianjin, 300070, China.
AD  - Key Laboratory of Immuno Microenvironment and Disease of the Educational Ministry 
      of China, Department of Immunology, Tianjin Medical University, Tianjin, 300070, 
      China.
FAU - Chen, L
AU  - Chen L
AD  - Key Laboratory of Hormones and Development (Ministry of Health), Tianjin Key 
      Laboratory of Metabolic Diseases, Tianjin Metabolic Diseases Hospital, Tianjin 
      Institute of Endocrinology, Tianjin Medical University, Tianjin, 300070, China. 
      xfx22081@vip.163.com.
FAU - Niu, W
AU  - Niu W
AD  - Key Laboratory of Hormones and Development (Ministry of Health), Tianjin Key 
      Laboratory of Metabolic Diseases, Tianjin Metabolic Diseases Hospital, Tianjin 
      Institute of Endocrinology, Tianjin Medical University, Tianjin, 300070, China. 
      wniu@tijmu.edu.cn.
AD  - Key Laboratory of Immuno Microenvironment and Disease of the Educational Ministry 
      of China, Department of Immunology, Tianjin Medical University, Tianjin, 300070, 
      China. wniu@tijmu.edu.cn.
LA  - eng
GR  - 81670731/National Natural Science Foundation of China/
GR  - 14JCYBJC26200/Natural Science Foundation of Tianjin City/
GR  - 15JCZDJC35500/Tianjin Municipal Science and Technology Commission/
GR  - 15KG102/Tianjin Health and Family Planning Commission/
GR  - 15ZXHLSY00460/Tianjin Municipal Science and Technology Commission/
PT  - Journal Article
DEP - 20180127
PL  - Italy
TA  - J Endocrinol Invest
JT  - Journal of endocrinological investigation
JID - 7806594
RN  - 0 (Glucose Transporter Type 4)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Insulin Receptor Substrate Proteins)
RN  - 0 (Irs1 protein, mouse)
RN  - 0 (Palmitates)
RN  - 0 (Slc2a4 protein, mouse)
RN  - 839I73S42A (Liraglutide)
SB  - IM
MH  - Animals
MH  - Cell Line
MH  - Glucose Transporter Type 4/metabolism
MH  - Humans
MH  - Hypoglycemic Agents/*pharmacology
MH  - Insulin Receptor Substrate Proteins/antagonists & inhibitors/*metabolism
MH  - Insulin Resistance/*physiology
MH  - Liraglutide/*pharmacology
MH  - Mice
MH  - Muscle Fibers, Skeletal/drug effects/*metabolism
MH  - Palmitates/*toxicity
MH  - Phosphorylation/drug effects/physiology
OTO - NOTNLM
OT  - IRS1 serine phosphorylation
OT  - Liraglutide
OT  - Skeletal muscle insulin resistance
EDAT- 2018/01/29 06:00
MHDA- 2019/01/01 06:00
CRDT- 2018/01/29 06:00
PHST- 2017/07/11 00:00 [received]
PHST- 2018/01/14 00:00 [accepted]
PHST- 2018/01/29 06:00 [pubmed]
PHST- 2019/01/01 06:00 [medline]
PHST- 2018/01/29 06:00 [entrez]
AID - 10.1007/s40618-018-0836-x [pii]
AID - 10.1007/s40618-018-0836-x [doi]
PST - ppublish
SO  - J Endocrinol Invest. 2018 Sep;41(9):1097-1102. doi: 10.1007/s40618-018-0836-x. 
      Epub 2018 Jan 27.